Optimising SARS-CoV-2 vaccination schedules
Optimising SARS-CoV-2 vaccination schedules
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
The SARS-CoV-2 humoral immune response has been used in early clinical trials as a surrogate marker of protection.4–6 However, the minimum titre of SARS-CoV-2 protein S neutralising antibodies to induce protection is unknown. Non-inferiority trials are randomised studies in which authors focus on whether an experimental arm is not clinically and st...
Alternative Titles
Full title
Optimising SARS-CoV-2 vaccination schedules
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8346239
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8346239
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(21)01729-3
